UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of September 2020

 

Commission File Number: 001-39458

 

Medicenna Therapeutics Corp.
(Translation of registrant's name into English)

 

2 Bloor St. W., 7th Floor
Toronto, Ontario M4W 3E2, Canada
(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.


Form 20-F [   ]      Form 40-F [ X ]

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [  ]

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [  ]

 

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  MEDICENNA THERAPEUTICS CORP.
       
       
       
Date: September 4, 2020 By:  /s/ Elizabeth Williams  
  Name: Elizabeth Williams
  Title: Chief Financial Officer

 

 

 

 

 

 

 

EXHIBIT INDEX

 

 

Exhibit Description
   
99.1 Notice of Meeting and Management Information Circular
99.2 Form of Proxy

 

 

 

 

 

 

 

 

 

 

 

 

Medicenna Therapeutics (NASDAQ:MDNA)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Medicenna Therapeutics Charts.
Medicenna Therapeutics (NASDAQ:MDNA)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Medicenna Therapeutics Charts.